EMN30-64007957MMY3003-MAJESTEC
Phase III
OPEN TO ACCRUAL
Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
UAB-21107-MASTER-2-MM
Phase II
OPEN TO ACCRUAL
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial